Last SFr.121.50 CHF
Change Today -0.70 / -0.57%
Volume 61.7K
BSLN On Other Exchanges
Symbol
Exchange
Berlin
SIX Swiss Ex
As of 12:53 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

basilea pharmaceutica-reg (BSLN) Snapshot

Open
SFr.122.20
Previous Close
SFr.122.20
Day High
SFr.123.50
Day Low
SFr.120.90
52 Week High
02/28/14 - SFr.129.60
52 Week Low
10/16/14 - SFr.79.75
Market Cap
1.2B
Average Volume 10 Days
80.3K
EPS TTM
SFr.-4.07
Shares Outstanding
10.2M
EX-Date
04/11/13
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BASILEA PHARMACEUTICA-REG (BSLN)

Related News

No related news articles were found.

basilea pharmaceutica-reg (BSLN) Related Businessweek News

No Related Businessweek News Found

basilea pharmaceutica-reg (BSLN) Details

Basilea Pharmaceutica AG, an integrated biopharmaceutical company, focuses on the discovery and development of pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections, and oncology in Switzerland and China. The company markets Toctino, a therapy for the treatment of adult patients with severe chronic hand eczema, who do not respond to potent topical corticosteroids. It is also developing Isavuconazole, a Phase III development antifungal drug for the treatment of invasive fungal infections; and Ceftobiprole, a bactericidal antibiotic for the treatment of hospital and community-acquired pneumonia, which is under regulatory review. In addition, the company is developing BAL30072, a monosulfactam antibiotic with bactericidal activity against multidrug-resistant gram-negative bacteria under Phase I clinical development; and BAL101553, a small-molecule anti-cancer drug in Phase I clinical development. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

230 Employees
Last Reported Date: 02/12/15
Founded in 2000

basilea pharmaceutica-reg (BSLN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.1.0M
Compensation as of Fiscal Year 2014.

basilea pharmaceutica-reg (BSLN) Key Developments

Basilea Pharmaceutica Ltd. Reports Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Basilea Pharmaceutica Ltd. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company total operating income of CHF 42.6 million compared to CHF 41.4 million a year ago. Operating loss was CHF 41.8 million compared to CHF 33.3 million a year ago. Net loss was CHF 41.5 million compared to CHF 33.0 million a year ago. Net cash used for operating activities was CHF 71.5 million compared to CHF 59.5 million a year ago. Basic and diluted loss per share was CHF 4.17 compared to CHF 3.40 a year ago. The company provided earnings guidance for the year 2015. Total operating expenses for 2015 are estimated at approximately CHF 9 million on average per month. Its average operating loss in 2015 is estimated at approximately CHF 4 million per month, with the vast majority of operating income driven by revenue recognition from upfront and milestone payments.

Basilea Pharmaceutica AG, 2014 Earnings Call, Feb 17, 2015

Basilea Pharmaceutica AG, 2014 Earnings Call, Feb 17, 2015

Basilea Pharmaceutica AG to Report Fiscal Year 2014 Results on Feb 17, 2015

Basilea Pharmaceutica AG announced that they will report fiscal year 2014 results on Feb 17, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSLN:SW SFr.121.50 CHF -0.70

BSLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BSLN.
View Industry Companies
 

Industry Analysis

BSLN

Industry Average

Valuation BSLN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.5x
Price/Book 22.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BASILEA PHARMACEUTICA-REG, please visit www.basileapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.